A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2b033c9903704388926ac8e5d4b2b0db |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2b033c9903704388926ac8e5d4b2b0db |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2b033c9903704388926ac8e5d4b2b0db2021-12-02T15:07:50ZA response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma10.1038/s41598-018-31027-y2045-2322https://doaj.org/article/2b033c9903704388926ac8e5d4b2b0db2018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-31027-yhttps://doaj.org/toc/2045-2322Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients.Qi ZhongJugao FangZhigang HuangYifan YangMeng LianHonggang LiuYixiang ZhangJunhui YeXinjie HuiYejun WangYing YingQing ZhangYingduan ChengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-8 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Qi Zhong Jugao Fang Zhigang Huang Yifan Yang Meng Lian Honggang Liu Yixiang Zhang Junhui Ye Xinjie Hui Yejun Wang Ying Ying Qing Zhang Yingduan Cheng A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| description |
Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients. |
| format |
article |
| author |
Qi Zhong Jugao Fang Zhigang Huang Yifan Yang Meng Lian Honggang Liu Yixiang Zhang Junhui Ye Xinjie Hui Yejun Wang Ying Ying Qing Zhang Yingduan Cheng |
| author_facet |
Qi Zhong Jugao Fang Zhigang Huang Yifan Yang Meng Lian Honggang Liu Yixiang Zhang Junhui Ye Xinjie Hui Yejun Wang Ying Ying Qing Zhang Yingduan Cheng |
| author_sort |
Qi Zhong |
| title |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| title_short |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| title_full |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| title_fullStr |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| title_full_unstemmed |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| title_sort |
response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
| publisher |
Nature Portfolio |
| publishDate |
2018 |
| url |
https://doaj.org/article/2b033c9903704388926ac8e5d4b2b0db |
| work_keys_str_mv |
AT qizhong aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT jugaofang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhiganghuang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yifanyang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT menglian aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT honggangliu aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yixiangzhang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT junhuiye aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT xinjiehui aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yejunwang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingying aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT qingzhang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingduancheng aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT qizhong responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT jugaofang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhiganghuang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yifanyang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT menglian responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT honggangliu responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yixiangzhang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT junhuiye responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT xinjiehui responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yejunwang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingying responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT qingzhang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingduancheng responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma |
| _version_ |
1718388373406613504 |